Two years ago, drug store chain CVS bought pharmacy benefits manager Caremark Rx, creating a company that is the largest buyer of pharmaceuticals in America. The combination was supposed to alter the pharmacy business forever. Since then, CVS Caremark's (NYSE:CVS) stock has dropped while its biggest competitor, Medco Health Solutions (NYSE:MHS), has risen. It seems that the retail pharmacy benefits management (PBM) business model wasn't a sure thing, and independents like Medco are continuing to do well, despite a recession. Perhaps that's why it's No.5 on Fortune Magazine's "World's Most Admired Companies" list. There's no question it's a great company, but is it a great stock?

IN PICTURES: 10 Ways To Prepare For Nature's Worst

Is an Acquisition in the Cards?

The Financial Times recently reported that Wellpoint (NYSE:WLP) was looking to sell its pharmacy benefits management business to focus on its managed care health plans, conceding that industry consolidation is just beginning. The Times suggested the sale could fetch between $1 billion and $5 billion in what's expected to be a very competitive auction. Medco is thought to be the leading candidate to possibly acquire the business, although other interested parties include CVS Caremark and the third-largest PBM, Express Scripts (Nasdaq:ESRX). Combining the largest (Medco) and fourth-largest (Wellpoint) PBMs is tempting, as it's already been capturing market share from CVS, its next biggest rival. My only concern is that it increased long-term debt by $1.1 billion in 2008. However, with $2.5 billion in EBITDA earnings in 2008, it easily can handle the added interest expense of an acquisition. Nonetheless, it's something to think about while many companies are tossing off debt wherever possible these days.

A Successful Year
In late February, Medco announced fourth-quarter and year-end results and they were exemplary. Revenues in 2008 grew 15.2% to $51.3 billion and net income 20.9% to $1.1 billion. Cash on hand at the end of December was just shy of $1 billion, generating $1.6 billion in cash flows from operations. The money is pouring in despite selling more lower cost generic drugs, which reduced revenues by $2.7 billion in 2008 but saved customers money in a very tough economy. Its total prescription volume for the year, mail order and retail combined, was 795.9 million, up 6.4% from 2007. Broken out, mail order prescription volumes grew 11.6% and retail prescriptions 3.3%. In addition, its specialty pharmacy, Accredo Health Group, generated $8 billion in revenues in 2008, a 32% increase year-over-year with operating income up 33.8% to $281.2 million. Looking ahead to the rest of 2009, Medco expects full-year GAAP diluted EPS of between $2.45 and $2.55, giving it a forward P/E of 15.8, the low-end of its projected EPS growth rate for the year.

Top Five PBMs by Market Share

Company Price-to-Sales
Medco Health Solutions
CVS Caremark Rx
Express Scripts
Affiliated Computer Services

The Future Looks Bright
As I said earlier, Medco is capturing market share. The debate rages on about whether it will continue to do so because CVS Caremark is putting extreme pricing pressure on Medco and its other competitors. On March 20, John Malley of Watson Wyatt Worldwide (NYSE:WW) told the Dow Jones Newswire that "CVS Caremark became extremely competitive in prices. They're very, very hard to beat."

While CVS Caremark may offer attractive drug prices to its employer customers, the retail chain would rather that end-user employees visit their stores to fill the prescriptions as opposed to doing so by mail order, which is cheaper. That way, the company can increase revenues on impulse purchases like chocolate bars and soda pop. Express Script's CEO believes operating both businesses is a conflict of interest. I don't know if I'd go that far, but certainly CVS Caremark is trying to play both sides of the street and you know what happens when you play in traffic - you get flattened. (To learn more about conflicts of interest, read Pages From The Bad CEO Playbook.)

The Bottom Line
Medco provides drug benefits to 20% of Americans. Given President Obama's desire to insure the 45 million or so people without health care coverage, I have a hard time believing this well-run business will lose its place at the front of the line. In the long term, you have to like its chances.

Related Articles
  1. Investing

    What’s Holding Back the U.S. Consumer

    Even as job growth has surged and gasoline prices have plunged, U.S. consumers are proving slow to respond and repair their overextended balance sheets.
  2. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  3. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  4. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  5. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  7. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  8. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  9. Economics

    A Look at Greece’s Messy Fiscal Policy

    Investigate the muddy fiscal policy, tax problems, and inability to institute austerity that created the Greek crises in 2010 and 2015.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. The New Deal

    A series of domestic programs designed to help the United States ...
  3. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  4. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  5. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  6. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. How does the risk of investing in the industrial sector compare to the broader market?

    There is increased risk when investing in the industrial sector compared to the broader market due to high debt loads and ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!